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The predominant tumor cell of Kaposi’s Sarcoma (KS) is the spindle cell, a cell of endothelial origin that
expresses markers of lymphatic endothelium. In culture, Kaposi’s Sarcoma-associated herpesvirus
(KSHV) infection of blood endothelial cells drives expression of lymphatic endothelial cell speciﬁc
markers, in a process that requires activation of the gp130 receptor and the JAK2/STAT3 and PI3K/AKT
signaling pathways. While expression of each of the KSHV major latent genes in endothelial cells failed
to increase expression of lymphatic markers, the viral homolog of human IL-6 (vIL-6) was sufﬁcient for
induction and requires the JAK2/STAT3 and PI3K/AKT pathways. Therefore, activation of gp130 and
downstream signaling by vIL-6 is sufﬁcient to drive blood to lymphatic endothelial cell differentiation.
While sufﬁcient, vIL-6 is not necessary for lymphatic reprogramming in the context of viral infection.
This indicates that multiple viral genes are involved and suggests a central importance of this pathway
to KSHV pathogenesis.
& 2012 Elsevier Inc. All rights reserved.Introduction
Kaposi’s Sarcoma (KS) is the leading cancer in parts of sub-
Saharan Africa and in AIDS patients world-wide (Antman and
Chang, 2000). KS is histopathologically characterized by having a
high degree of angiogenesis, inﬁltrating immune and red blood
cells, and is predominantly comprised of spindle cells, which
are of endothelial origins and speciﬁcally express markers of
lymphatic endothelium (Boshoff et al., 1995; Jussila et al., 1998;
Skobe et al., 1999). In addition, KS tumors have elevated levels of
many cytokines and growth factors, including interleukin-1 (IL-1),
IL-6, basic ﬁbroblast growth factor (bFGF), platelet derived
growth factor (PDGF), tumor necrosis factor (TNF), interferon
gamma (IFN-g), and vascular endothelial growth factor (VEGF)
(Ensoli et al., 2001, 2000; Wang et al., 2004).
Kaposi’s Sarcoma-associated herpesvirus (KSHV or human herpes-
virus-8) is the etiologic agent of KS, and is classiﬁed as a gamma-2-
herpesvirus (Aluigi et al., 1996; Chang et al., 1994). The KS spindle cell
is infected by KSHV, with greater than 95% of cells latently infected
and 1–5% of cells undergoing lytic replication (Staskus et al., 1997).
KSHV encodes over 90 genes, but only a few genes are expressedll rights reserved.
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agunoff).during latency in KS tumors and KSHV-infected endothelial cells in
culture: latency associated nuclear antigen (LANA), viral Cyclin, viral
FLICE inhibitory protein (vFLIP) (Dittmer et al., 1998; Staskus et al.,
1997), the kaposin family (Sadler et al., 1999), and 17 or more
microRNAs (Cai et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005;
Samols et al., 2005). Additionally, several KSHV lytic genes have been
proposed to contribute to KS pathogenesis in an autocrine or
paracrine fashion from the small percentage of lytically infected cells
found in KS tumors. Some of these genes include: a constitutively
active viral G-protein coupled receptor (vGPCR); K1, which signals
through a constitutive ITAM (immunoreceptor tyrosine-based activa-
tion motif), K15, a membrane protein with SH2 and SH3 protein
binding domains and vIL-6, a viral homolog of human IL-6
(Brinkmann et al., 2003; Couty and Gershengorn, 2004; Lagunoff
et al., 1999; Molden et al., 1997). Interestingly, transcripts for K1 and
vIL-6 were recently shown to be detectable in dilutions of primary
effusion lymphoma cells where other lytic genes could no longer be
detected, indicating there may be some previously unappreciated
low-level of expression of these genes during latency (Chandriani and
Ganem, 2010). Additionally, there are speciﬁc situations where vIL-6
expression can be induced during latency. For example, it was shown
that interferon could activate expression of vIL-6 in primary effusion
lymphoma (PEL) cells (Chatterjee et al., 2002).
KSHV infection of blood endothelial cells (BECs) induces their
differentiation to lymphatic endothelial cells (LECs) (Carroll et al.,
2004; Hong et al., 2004; Wang et al., 2004). BECs and LECs line the
Fig. 1. Transient expression of latent genes do not induce lymphatic differentia-
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express around 300 genes (Hirakawa et al., 2003). During embryonic
development, the blood vessel system develops ﬁrst, then BECs
differentiate into LECs in the cardinal vein when an unknown signal
induces the expression of the homeobox transcription factor Prox1
(Hong and Detmar, 2003; Hong et al., 2002; Petrova et al., 2002).
Prox1 is a transcriptional repressor and activator, and is the master
regulator of lymphatic differentiation (Hong and Detmar, 2003; Hong
et al., 2002; Petrova et al., 2002). Following Prox1 induction, vascular
endothelial growth factor receptor 3 (VEGFR-3) is expressed on LECs
and is responsible for budding and formation of early lymph vessels
through binding its ligand VEGF-C (Veikkola et al., 2001). Podoplanin,
a cell surface glycoprotein induced by Prox1 expression, is involved in
later stages of lymphatic vasculature development (Schacht et al.,
2003). KSHV infection of primary BECs or telomerase-immortalized
microvascular endothelial (TIME) cells, which resemble BECs in gene
expression proﬁle, induces the expression of Prox1, VEGFR-3 and
podoplanin (Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004).
The viral mechanism of KSHV-induced endothelial cell differentia-
tion is poorly understood. Previously, we found that KSHV induction
of lymphatic differentiation is dependent on the activation of the
cytokine receptor gp130, and the resulting initiation of JAK2/STAT3
and PI3K/AKT intracellular signaling pathways (Morris et al., 2008;
Punjabi et al., 2007). In addition, the latently expressed kaposin B was
recently shown to stabilize Prox1 mRNA, leading to an increase
in expression of Prox1 and its downstream-activated genes, such as
VEGFR-3 (Yoo et al., 2010). However, kaposin B expression was
unable to induce the expression of Prox1 in cells that do not already
express Prox1, namely blood endothelial cells. This suggests that
there must be a viral gene that initially induces the expression of
Prox1 and lymphatic endothelial cell differentiation, and kaposin B
subsequently increases or maintains expression of genes involved in
the differentiation phenotype.
KSHV-encoded vIL-6 shares 25% homology with human IL-6,
but can bind the gp130 receptor directly and signal independent of
the cognate IL-6 receptor (gp80) to initiate similar intracellular
signaling pathways (Li et al., 2001; Molden et al., 1997; Moore
et al., 1996; Nicholas et al., 1997; Wan et al., 1999). In PEL cells,
which are KSHV-infected, vIL-6 promotes proliferation of cells,
protects cells from apoptosis, and also promotes immune evasion of
interferon activity (Chatterjee et al., 2002; Foussat et al., 1999; Jones
et al., 1999). vIL-6 can also promote angiogenesis through induction
of VEGF A (Aoki et al., 1999). In this report, we show that the genes
from the major latency locus do not have the capacity to induce
lymphatic endothelial cell markers when expressed individually.
Interestingly, expression of KSHV vIL-6 is sufﬁcient to induce the
LEC-speciﬁc markers Prox1, VEGFR-3, and podoplanin. We also
extend previous ﬁndings that vIL-6 is not necessary in the context
of KSHV infection, and demonstrate that vIL-6 is not the soluble factor
released by KSHV-infected cells that activates gp130 receptor signal-
ing (Morris et al., 2008; Punjabi et al., 2007). Thus, while vIL-6
is sufﬁcient for endothelial cell differentiation, another unidentiﬁed
viral protein directly activates or induces a novel cytokine that
activates the same pathway during latency. The presence of multiple
viral factors that induce the same pathway suggests that this
cytokine-signaling pathway plays a central role in KSHV pathogenesis
and KS tumor formation.tion. (A) Constructs expressing individual latent viral genes were transiently
transfected into TIME cells. 48 h post transfection, cell lysates were harvested and
subjected to immunoblot analysis with the indicated antibodies. In addition,
stable pooled TIME cells expressing LANA or a retroviral vector control were
similarly analyzed. While expression of individual latent viral genes was con-
ﬁrmed by FLAG or LANA immunoblot, no viral gene activated STAT3 or induced
VEGFR-3 expression. (B) TIME cells (2105) were transduced with lentiviral preps
of the indicated KSHV latent genes or pCGSW, a control lentivirus that expresses
GFP. 72 hpi, cell lysates were harvested and subjected to immunoblot analysis
with the indicated antibodies. TIME cells were mock or KSHV-infected and
harvested 48 hpi for positive and negative controls respectively.Results
KSHV latent genes do not activate gp130 receptor signaling or
lymphatic differentiation of endothelial cells
In previous reports, we determined that viral gene expression is
necessary to maintain KSHV-induced STAT3 activation and lymphaticreprogramming (Morris et al., 2008; Punjabi et al., 2007). These
results suggest that viral genes are required for the constant activa-
tion of the gp130 receptor signaling pathway. Since latently infected
TIME cells express LEC-speciﬁc markers and display persistent STAT3
activation (Carroll et al., 2004; Punjabi et al., 2007), we hypothesized
that one or more of the latent genes are responsible for KSHV-
induced activation of gp130 receptor signaling and thus lymphatic
differentiation of endothelial cells. The latent genes viral Cyclin (vCyc),
kaposin A (KapA), kaposin B (KapB), and kaposin C (KapC) were
cloned into a mammalian expression vector with an N-terminal
3XFLAG epitope-tag and expressed in TIME cells. Additionally,
we obtained a mammalian expression vector encoding a highly
expressed codon-optimized FLAG-tagged vFLIP, which was also
expressed in TIME cells (P. Bellare and D. Ganem, unpublished data).
Previous studies have veriﬁed the functionality of N-terminally
tagged vCyc, vFLIP, and KapA (Montaner et al., 2003). We veriﬁed
the expression of all constructs by transient transfection into TIME
cells followed by immunoblot analysis with an anti-FLAG antibody
(Fig. 1A, bottom panel). Anti-vCyc and anti-kaposin antibodies were
used to verify the expression of the FLAG-tagged vCyc, KapB, and
KapC constructs (data not shown). The transfection efﬁciency was
50–70%, as determined by transfection of TIME cells with a plasmid
encoding green ﬂuorescent protein (GFP) and monitoring expression
by ﬂuorescence microscopy (data not shown). At 48 h post infection,
cells were harvested for Western blot analysis. None of the latent
viral proteins tested activated STAT3, as determined by STAT3
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sion (Fig. 1A and not shown). We also created a stable pooled TIME
cell line expressing LANA or an empty vector control cell line (pZIP)
using retroviral transduction, followed by puromycin selection.
Although the expression of LANA in these cells was conﬁrmed by
immunoblot analysis with an anti-LANA antibody (Fig. 1A, lower right
panel), LANA expression was not sufﬁcient to induce persistent STAT3
phosphorylation or VEGFR-3 expression in TIME cells when compared
to the vector control cell line. These results indicate that transient
expression of the individual latent genes, LANA, vCyc, KapA, KapB,
KapC, or vFLIP, is not sufﬁcient to induce gp130 receptor activation or
lymphatic differentiation. Furthermore, we did not see STAT3 phos-
phorylation when all of the latent gene constructs were co-trans-
fected into TIME cells, although expression levels were lower than
when they were transfected individually (data not shown).
To examine longer-term expression of the latent genes in a
higher percentage of cells, we obtained lentiviral vectors of the
latent genes, including K12 (KapA), ORF71 (vFLIP), ORF72 (vCyc),
and ORF73 (LANA). Infectious lentivirus containing each major
latent gene was used to infect TIME cells. TIME cells were
transduced with the KSHV lentiviral library and expression of
the viral genes was conﬁrmed for each by qRT-PCR with latent
gene speciﬁc primers (see Supplemental Fig. 1). TIME cells were
infected with the different lentiviral preparations in parallel, and
protein lysates were harvested at 72 hpi. Mock- and KSHV-
infected TIME cell lysates harvested 48 hpi were used as negative
and positive controls respectively. As with the transient transfec-
tions, none of the genes from the latent locus were able to induce
STAT3 activation, AKT activation as determined by phoshphoryla-
tion at Ser473 or lymphatic endothelial cell markers (Fig. 1B).
KapB was previously reported to stabilize the mRNA of Prox-1 and
subsequently increase VEGFR3 expression in LECs, though it did
not induce the expression of Prox-1 in BECs (Yoo et al., 2010). To
conﬁrm this in TIME cells, we used a lentivirus vector to express a
FLAG-tagged KapB protein. As expected, KapB expression did not
induce any Prox-1 transcription in TIME cells as determined by
quantitative RT-PCR (data not shown).
KSHV vIL-6 induces LEC-speciﬁc markers in TIME cells
Since expression of KSHV latent genes did not activate STAT3
or induce LEC-speciﬁc markers, we postulated that the small
percentage of lytically infected TIME cells could be producing a
paracrine factor to activate the gp130 receptor. Additionally, a
recent publication found that vIL-6 mRNA could be detected by
PCR in dilutions of PEL cells where many other lytic mRNAs could
not be detected (Chandriani and Ganem, 2010). Therefore, we
tested vIL-6 and a select number of KSHV lytic genes for activa-
tion of the gp130 receptor by transient transfection. These include
K14 (vOX2), hemagglutinin (HA)-tagged K3 (MIR1), FLAG-tagged
K5 (MIR2), or the vector controls pBMN-ZIN and pLNCX2. Of the
genes tested, only vIL-6 was able to activate STAT3 and turn on
expression of VEGFR3 (Fig. 2A). To determine if KSHV ORF50 (Rta),
the lytic switch gene, activates STAT3 and lymphatic differentia-
tion, we infected TIME cells with an adenovirus vector expressing
Rta. While the levels of Rta used were sufﬁcient to induce lytic
reactivation in latently infected cells, in uninfected cells Rta
expression did not lead to activation of STAT3 and did not
increase Prox-1 expression (data not shown).
We next used a lentiviral expression library of select KSHV
genes: K1, K2 (vIL-6), K3 (MIR1), ORF28, K6 (vMIP), K8 (K-bZIP), K9
(vIRF1), K11.1 (vIRF2), ORF74 (vGPCR), and K15-P (LAMP) to test
which KSHV lytic genes could induce lymphatic endothelial cell
differentiation. This lentiviral library was previously used to
identify the viral genes that induce Ang2 expression in endothelial
cells (Vart et al., 2007). Again, K2 (vIL-6) was the only viral genetested that induced persistent STAT3 phosphorylation (Fig. 2B and
data not shown). Conditioned media from cells transduced with
each KSHV gene examined was also tested for activation of STAT3
and again, only conditioned media from vIL-6 expressing cells led
to phosphorylation of STAT3 (Supplemental Fig. 2). Interestingly,
vGPCR and K1 induced low levels of AKT activation in this assay
while in cells with long-term vIL-6 expression the levels of
phosphorylated AKT were at our limits of detection. However, as
described below and seen in Fig. 5B, treatment of cells with
conditioned media containing vIL-6 induces stronger activation
of AKT indicating that vIL-6 can transiently induce AKT. Overall,
this data indicates that activation of AKT is important for blood to
lymphatic endothelial cell differentiation, but activation of AKT
alone is not sufﬁcient to induce blood to lymphatic endothelial cell
differentiation as both K1 and vGPCR induce the activation of AKT
but do not activate STAT3 or signiﬁcantly increase the expression
of VEGFR3.
We then selected for cells that had been transduced with a
retrovirus expressing vIL-6 or a vector control to make a stable
vIL-6 cell line and a passage matched control vector cell line
(pBMN-ZIN). The stable vIL-6 TIME cell line induced long-term
activation of STAT3 and long-term VEGFR-3 and podoplanin
protein expression similar to levels seen in KSHV infected cells
as determined by Western blot analysis (Fig. 3A). There were also
highly induced levels of Prox1 mRNA in vIL-6 stable cells but not
in the vector control cells (Fig. 3B). Prox1 is the transcription
factor necessary for the induction of lymphatic differentiation
in vivo and in vitro. Previously, we determined that gp130
receptor expression is induced by KSHV infection of TIME cells,
and this induction was controlled by STAT3 activation (Morris
et al., 2008; Punjabi et al., 2007). Accordingly, we also observed an
increase in gp130 mRNA induction in the vIL-6-expressing TIME
cells (Fig. 3B). These results demonstrate that vIL-6 expression is
sufﬁcient to activate gp130 receptor signaling and induce lym-
phatic differentiation of TIME cells.
KSHV vIL-6 induces LEC-speciﬁc markers in primary blood
endothelial cells
The previous analysis was performed in an immortalized blood
endothelial cell line, TIME cells. We also conﬁrmed that vIL-6 was
sufﬁcient to reprogram primary human dermal blood microvas-
cular endothelial cells (BECs) to express lymphatic endothelial
cell markers. Primary BECs (Lonza) were transduced with a
lentivirus expressing vIL-6 or the control vector lentivirus pCGSW
and lysates were harvested 72 h after transduction. Immunoblot
analysis shows that vIL-6 induces the activation of STAT3 and the
expression of VEGFR3 in primary BECs (Fig. 4).
vIL-6 induction of lymphatic differentiation requires JAK2/STAT3 and
PI3K/AKT signaling
We observed persistent phosphorylation of STAT3 in stable vIL-6
expressing TIME cells, but very weak phosphorylation of AKT
(Fig. 2B). We therefore wanted to determine if JAK2/STAT3 and
PI3K/AKT signaling were necessary for vIL-6 activation of lymphatic
endothelial cell markers. TIME cells expressing vIL-6 were treated
with pharmacological inhibitors of PI3K (LY294002), and of JAK2
(AG490). Both inhibitors blocked vIL-6 induced expression of
VEGFR3 and podoplanin (Fig. 5A). Therefore, as with KSHV latent
infection, both JAK2/STAT3 and PI3K/AKT signaling is necessary for
induction of lymphatic endothelial cell reprogramming by vIL-6.
Since the levels of AKT activation in the vIL-6 cell line was at
the limit of detection, we tested whether vIL-6 could transiently
activate AKT in TIME cells. Conditioned media from vIL-6-expres-
sing or control pBMN-ZIN TIME cells were harvested, and used to
Fig. 2. Expression of vIL-6 but not other lytic genes that activate AKT induce lymphatic differentiation. (A) TIME cells expressing the lytic viral proteins vIL-6, vOX2, HA-K3,
or FLAG-K5 were created by retroviral transduction and antibiotic selection. Cell lysates were assayed by immunoblot analysis with the indicated antibodies. Stable vIL-6
expression induced VEGFR-3 expression and activated STAT3. (B) TIME cells (2105) were transiently transduced with lentiviral preps of the indicated KSHV lytic genes or
a control lentivirus (pCGSW). 72 hpi, cell lysates were harvested and subjected to immunoblot analysis with the indicated antibodies. TIME cells were mock or KSHV-
infected and harvested 48 hpi for positive and negative controls respectively.
Fig. 3. Stable vIL-6 expression in TIME cells induces LEC-speciﬁc markers. (A) Stable vIL-6-expressing TIME cells induce VEGFR-3 and podoplanin expression compared to
stable TIME cells expressing retroviral vector alone (pBMN-ZIN) as determined by immunoblot analysis. Mock and KSHV-infected TIME cells harvested 48 hpi were used as
negative and positive controls. Stable vIL-6-expressing TIME cells also display persistent activation of STAT3 (B) Stable vIL-6-expressing TIME cells induce Prox1 and
gp130 mRNA expression as determined by quantitative real-time RT-PCR. Error bars represent standard error of the mean (n¼3).
Fig. 4. vIL-6 reprograms primary blood endothelial cells to express lymphatic
markers. Primary human blood microvascular endothelial cells (BECs) (2105)
were transiently transduced with lentiviral preps of vIL-6 lytic or control
lentivirus (pCGSW). 72 hpi, cell lysates were harvested and subjected to immuno-
blot analysis with the indicated antibodies. Primary BECs were mock or KSHV-
infected and harvested 48 hpi for positive and negative controls respectively.
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were transiently phosphorylated in cells treated with conditioned
media from vIL-6-expressing TIME cells (Fig. 5B). This result
indicates that while vIL-6 expression persistently activates STAT3
in TIME cells, AKT activation is mostly transient. However, there
appears to be some low-level activation of AKT in long term vIL-6
expressing endothelial cells as the PI3 kinase inhibitor, LY294002inhibited vIL-6 activation of VEGFR3. However, because long-term
activation is at our limit of detection, it was not seen consistently
in every experiment. Nonetheless, this indicates that vIL-6 can, at
least transiently, activate AKT signaling and this activation is
necessary for the induction of lymphatic markers by vIL-6.
vIL-6 is not essential for activation of gp130 receptor signaling in
KSHV-infected endothelial cells
While vIL-6 expression alone is sufﬁcient to induce STAT3
activation in TIME cells, we previously showed that vIL-6 is not
necessary for activation of STAT3 nor the induction of LEC-speciﬁc
markers in the context of KSHV infection (Punjabi et al., 2007).
For those experiments, we used a recombinant virus where
more than half of the ORFK2 gene encoding vIL-6 is deleted, and
infected TIME cells with either vIL-6-positive or negative-recom-
binant KSHV isolates. In both cases, we observed phosphorylation
of STAT3 and induction of VEFGR-3 and podoplanin (Chen and
Lagunoff, 2007; Morris et al., 2008; Punjabi et al., 2007). However,
it is still possible that vIL-6 plays a signiﬁcant role in the activation
of STAT3 and VEGFR3 that is masked by comparing the infections
of the recombinant virus versus the control virus. Additionally, the
deletion of vIL-6 leaves a small portion of the gene intact, though
Fig. 5. vIL-6 induction of lymphatic differentiation requires JAK2/STAT3 and PI3K/AKT. (A) The PI3K inhibitor LY294002 (LY) and the JAK2 inhibitor AG490 (AG) block
VEGFR-3 and podoplanin expression in stable vIL-6-expressing TIME cells. The numbers below the lanes indicated the relative abundance of VEGFR-3 and podoplanin
expression normalized to b-actin expression in each lane compared to expression in the untreated vIL-6 expression cells. (B) Conditioned media harvested from stable
vIL-6-expressing TIME cells transiently induces AKT and STAT3 phosphorylation in serum starved TIME cells treated for 30 min.
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recombinant (Chen and Lagunoff, 2007). To determine if vIL-6 is
the dominant gp130-activating factor and that the infection with
the recombinant is not equivalent to infection with the control, we
used lentivirus-mediated delivery of shRNA speciﬁc to vIL-6. TIME
cells were infected with KSHV, and subsequently infected with
lentivirus expressing vIL-6 shRNA or a negative control nonspeciﬁc
shRNA (NS) (Chen et al., 2009). By quantitative real-time RT-PCR,
we observed a 60% decrease in vIL-6 mRNA in the vIL-6 versus the
NS shRNA transduced KSHV-infected cells, normalizing to cellular
GAPDH mRNA levels (data not shown and (Chen et al., 2009)).
Importantly, there was no decrease in mRNA levels of the latent
gene LANA, indicating the establishment of KSHV infection was
not impaired (data not shown). However, vIL-6 shRNA did not
signiﬁcantly decrease KSHV induction of VEGFR-3 or STAT3
activation (Fig. 6A)
In the next set of experiments we examined the ability of the
shRNA to block activation of STAT3 by conditioned media from KSHV
infected TIME cells and from vIL-6 expressing TIME cells to determine
if vIL-6 is the dominant factor in transient activation of STAT3 in
KSHV infected cells. TIME cells were co-transduced with a K2 (vIL-6)
expressing lentivirus and either vIL-6 speciﬁc or NS shRNA lenti-
viruses and the conditionedmedia was harvested 48 h later. The vIL-6
speciﬁc shRNA strongly inhibited the activation of STAT3 by condi-
tioned media from vIL-6 expressing cells (Fig. 6). However, there was
little or no decrease in the activation of STAT3 by conditioned media
from KSHV-infected cells in the presence of vIL-6 speciﬁc shRNA,
indicating that vIL-6 is not necessary for a signiﬁcant portion of the
activation of gp130 by conditioned media during de novo KSHV
infection. This set of experiments shows that the vIL-6-independent
activation of STAT3 and lymphatic differentiation is likely the
predominant pathway in latent KSHV-infected cells.Discussion
KSHV infection of endothelial cells, the main cell type of KS
tumors, induces the aberrant activation of the cytokine receptor
gp130, resulting in the persistent activation of the JAK2/STAT3 and
PI3K/AKT signaling pathways. These pathways result in KSHV-
mediated transcriptional reprogramming of endothelial cells to aLEC differentiation state (Morris et al., 2008). In this study we sought
to determine whether speciﬁc viral proteins could activate gp130
receptor signaling or LEC-speciﬁc genes. Using transient transfection
or lentiviral transduction of individual viral genes, we could not
identify a latent protein that activated STAT3 or induced LEC-speciﬁc
markers. We went on to test a number of lytic genes that have been
previously shown to play a role in KSHV pathogenesis during latency
through cytokine signaling or other paracrine effects. Interestingly,
although the KSHV lytic proteins vGPCR and K1 can activate PI3K/AKT
signaling in other systems (Sodhi et al., 2004; Wang et al., 2006),
individual expression of these viral genes did not induce lymphatic
reprogramming in TIME cells indicating that activation of PI3K/AKT
signaling alone is not sufﬁcient for BEC to LEC differentiation. A
number of other lytic genes that can act as cytokines like the vMIPs
were also unable to activate STAT3 signaling or induce LEC-speciﬁc
markers. However, we found that KSHV-encoded vIL-6, which can
bind and activate the gp130 receptor, induces LEC-speciﬁc markers
through activation of both JAK2/STAT3 and PI3K/AKT signaling path-
ways. Interestingly, both STAT3 and AKT are phosphorylated early
after KSHV infection of endothelial cells, dephosphorylated at 4–8 hpi
and then constitutively activated after 12 h (Punjabi et al., 2007;
Sadagopan et al., 2007). The early activation of STAT3 is due to viral
binding and entry while the late activation of STAT3 is due to viral
gene expression as UV-irradiated virus only activates the early
wave of STAT phosphorylation (Punjabi et al., 2007). We previously
published that in latently infected cells gp130 signaling was neces-
sary for KSHV induced differentiation of blood endothelial cells to
lymphatic. Here we found that activation of these pathways by vIL-6
expression alone was sufﬁcient to induce lymphatic reprogramming
of both TIME and primary microvascular blood endothelial cells.
Additionally, while it was known that vIL-6 could activate STAT3
through the gp130 receptor, we found here that at least transiently,
vIL-6 could activate AKT. While vIL-6 has been shown to predomi-
nantly signal through intracellular pathways, we found that condi-
tioned media from cells expressing vIL-6 could also activate STAT3
and AKT indicating it can act both cell autonomously and as a
paracrine factor.
Our previous studies found that blood to lymphatic differen-
tiation only occurs in latently infected cells as determined by
co-immunoﬂuorescence with LANA and LEC-speciﬁc markers
in KSHV infected TIME cells (Morris et al., 2008). Additionally,
Fig. 6. Knockdown of vIL-6 inhibits conditioned media from vIL-6 expression cells from inducing STAT3 but not from KSHV infected cells. (A) TIME cells were infected with KSHV,
24 hpi cells were transduced with lentiviruses encoding nonspeciﬁc shRNA (NS) or a vIL-6-speciﬁc shRNA. Cell lysates were harvest 48 h after transduction and subjected to
immunoblot analysis with the indicated antibodies. Knockdown of vIL-6 had little or no effect on expression of lymphatic genes or STAT3 activation in infected cells. The numbers
below the lanes indicated the relative abundance of phospho-STAT3 normalized to total STAT3 expression in each lane compared to expression in the NS control cells. (B) TIME
cells were infected and transduced with vIL-6 speciﬁc or nonspeciﬁc shRNAs as in A. At 40 h post lentiviral transduction, the media was changed, conditionedmedia was harvested
8 h later and used to treat serum-starved TIME cells for 30 mins. As a control for vIL-6 knockdown, vIL-6 expressing TIME cells were concurrently infected with the shRNA
lentiviruses and either pCGSW or vIL-6 expressing lentivirus. The vIL-6 shRNA decreased the phosphorylation of STAT3 by conditioned media harvested from control vIL-6
expressing cells (lanes 7 and 8), but not from KSHV-infected cell conditioned media (lanes 3 and 4). The numbers below the lanes indicated the relative abundance of phospho-
STAT3 normalized to total STAT3 expression in each lane compared to expression in the NS control cells.
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to Prox1 (Yoo et al., 2010). Therefore, it is likely that there is a
factor expressed only in latently infected cells that is critical for
KSHV induced BEC to LEC differentiation. A recent study found
that kaposin B, a KSHV gene that is expressed during latency, was
able to stabilize Prox-1 mRNA through sequences in its 3’UTR
(Yoo et al., 2010) However, kaposin B alone was not sufﬁcient to
induce expression of Prox1 in BECs. Therefore, two events must
occur: (1) KSHV induces the expression of Prox-1 and (2) once
expressed, kaposin B stabilizes and effectively increases expres-
sion of Prox-1 to drive differentiation. Therefore, a lytic gene
could theoretically induce the expression of Prox-1 to low levels
in a paracrine fashion while kaposin B stabilizes and effectively
increases the expression of Prox-1 to levels sufﬁcient to fully
drive BEC to LEC differentiation in the latently infected cells but
not the surrounding uninfected cells. While we demonstrate here
that vIL-6 is certainly sufﬁcient to turn on the expression of Prox-
1 and could act as this paracrine factor, it is not essential for KSHV
induced BEC to LEC differentiation. This indicates that KSHV
expresses another gene that is capable of activating STAT3, AKT
and lymphatic reprogramming. We found that vIL-6 is unlikely to
play the predominant role in activation of gp130 signaling during
latent infection as knockdown of vIL-6 did not decrease the
activation of gp130 signaling in KSHV infected cells or from KSHV
conditioned media but was able to signiﬁcantly decrease para-
crine signaling from vIL-6 expressing cells. This suggests that
another viral gene(s) is expressed during latency that is respon-
sible for gp130 receptor signaling, or there is another untested
lytic gene capable of activating gp130 in a paracrine fashion. It is
also possible that the 17 or more KSHV miRNAs play a signiﬁcant
role in the regulation of this pathway. Further work is underway
to determine if expression of the KSHV miRNAs alter endothelial
cell differentiation. Nonetheless, our ﬁndings imply that there are
redundant methods used by KSHV to activate the gp130 receptor
and lymphatic reprogramming, which would predict an impor-
tant role for this signaling pathway in KSHV pathogenesis.Materials and methods
Reagents and antibodies
Phospho-AKT (Ser473), pan AKT, phospho-STAT3 (Y705) and
pan STAT3 antibodies (Cell Signaling Technologies) were used as
speciﬁed by the manufacturer. Antibodies to b-actin (Sigma),ORF59 (Advanced Biotechnologies, Inc.), LANA (Advanced Bio-
technologies, Inc. and kind gift of D. Ganem), gp130, VEGFR-3
(Santa Cruz Biotechnologies), and podoplanin (Abcam) were used
in immunoblot or immunoﬂuorescence analysis as outlined
below. Kinase inhibitors AG490 and LY294002 (Calbiochem) were
reconstituted in DMSO and used at the concentrations speciﬁed.
Cells
TIME cells and primary dermal blood microvascular endothelial
cells (Lonza) were maintained as monolayer cultures in EGM-2
media [Lonza (Lagunoff et al., 2002; Venetsanakos et al., 2002)].
BCBL-1 cells (Renne et al., 1996) were maintained in RPMI 1640
media (Cellgro, Mediatech, Inc.) supplemented with 10% fetal
bovine serum, penicillin, streptomycin, L-glutamine and b-mer-
captoethanol. HEK293T cells and Phoenix-ampho packaging cell
lines were obtained from American Type Culture Collection (ATCC)
and were maintained in DMEM (Cellgro, Mediatech, Inc.) supple-
mented with 10% fetal bovine serum, penicillin, streptomycin, and
L-glutamine.
KSHV viruses and infections
KSHV inoculum, from BCBL-1 cells, was used to infect TIME cells
as previously described (Lagunoff et al., 2002; Punjabi et al., 2007).
Brieﬂy, KSHV infections of TIME cells were performed in serum free
EBM-2 media for 3 h, after which the media was replaced with
complete EGM-2 containing serum and supplements. Infection
rates were assessed by immunoﬂuorescence using antibodies
against the latent protein LANA and the lytic protein ORF59 and
only experiments with greater than 90% LANA positive cells and
less than 1% ORF 59 positive cells were used.
Plasmids
The KSHV latent genes vCyclin and kaposin A were cloned by
PCR into the 3XFLAG-CMV-10 expression vector (Sigma) using KpnI
and XbaI restriction sites, and kaposin B and C were subcloned from
pCR3.1 into the HindIII and EcoRI restriction sites (pCR3.1-kaposin B
and pCR3.1-kaposin C plasmids obtained from Craig McCormick,
Dalhousie University). FLAG-vFLIP with codons optimized for
expression was a kind gift from Don Ganem (University of Califor-
nia San Francisco, P. Bellare and D. Ganem, unpublished data). A
retroviral plasmid encoding LANA, pBABE-LANA, was a kind gift
from Adam Grundhoff (Heinrich-Pette-Institute for Experimental
V.A. Morris et al. / Virology 428 (2012) 112–120118Virology and Immunology, University of Hamburg). The following
retroviral expression vectors were used: pLNCX2 (Clontech);
hemaglutinin-tagged K3, pLNCX-HA-K3; FLAG-tagged K5, pBMN-
FLAG-K5; pLNCX-K14 [kind gifts from Laurant Coscoy, University
of California Berkley (Coscoy and Ganem, 2000)]; pBMN-ZIN; and
pBMN-vIL-6 (vIL-6 cloned by PCR into the BamH1 and EcoR1 sites
of pBMN-ZIN). Lentiviral packaging plasmids psPAX2 and pMD2.G
were obtained from Addgene (supplied by Dr. Didier Trono).
Lentiviral expression plasmids pSIN-MCS containing KSHV genes
(Vart et al., 2007) or pCGSW (Godfrey et al., 2005) encoding GFP
were described elsewhere. Lentiviral shRNA vectors to vIL-6 and
nonspeciﬁc, nonsilencing (NS) control are described elsewhere
[gifts from John Nicholas, Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University School of Medicine (Chen et al.,
2009)].
Transient transfection of plasmids by Amaxa nucleofection
TIME cells (1106 cells) were transfected with 4 mg of the
plasmids encoding the latent genes using the Amaxa Nucleofector
(Koeln, Germany) according to the manufacturer’s protocol. 72 h
post transfection, cells were harvested and analyzed by immuno-
blot analysis.
Immunoblot analysis
Cells were harvested and resuspended in RIPA lysis buffer
(50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM sodium
orthovanadate, 1 mM sodium ﬂuoride, 40 mM b-glyceropho-
sphate, and Complete Mini Protease Inhibitor Tablet [Roche]), cell
debris was removed after a 20 min incubation by centrifugation.
Protein concentrations were determined by BCA assay (Pierce) and
10 mg protein was fractionated on a sodium dodecyl sulfate-
polyacrylamide gel, transferred to polyvinyl diﬂuoride membrane,
blotted with the appropriate antibody (dilutions were 1:1000 for
anti-pAKT, anti-AKT anti-pSTAT3, anti-STAT3, anti-gp130, anti-
VEGFR-3; 1:2500 for anti-podoplanin; and 1:10,000 anti-b-actin),
and subsequently probed with horse radish peroxidase-conju-
gated goat anti-mouse or -rabbit immunoglobulin G (Jackson
ImmunoResearch Laboratories). Immunoreactive proteins were
visualized by chemiluminescence using Amersham ECL Plus.
Differences in band intensity were quantiﬁed by densitometric
methods (ImageJ program).
RNA isolation and quantitative RT-PCR
Total RNA was isolated from TIME cells using the RNeasy Plus
kit (Qiagen). 100 or 500 ng of total RNA was used in SuperScript
III, Platinum SYBR green, one-step quantitative reverse transcrip-
tion PCR (RT-PCR) (Invitrogen) according to manufacturer’s pro-
tocols with the primers for either GAPDH (glyceraldehydes-3-
phosphate dehydrogenase) (forward: 50- GGA CTC ATG ACC ACA
GTC CA-30, reverse: 50- CCA GTA GAG GCA GGG ATG AT-30), Prox1
(forward: 50-AGT GCA ATG CAG GAA GGA TT-30, reverse: 50-CCA
CTT GAT GAG CTG AGA GG-30), gp130 (forward: 50-GAG CCA GAT
TCC TCC TGA AG-30, reverse: 50-CCA CTT GCT TCT TCA CTC CA-30).
Relative abundances of the indicated mRNAs were normalized by
the delta threshold cycle method to the abundance of GAPDH,
with mock-infected TIME cells set to 1. Error bars reﬂect standard
errors of the mean (three experiments).
Retrovirus production and infection of TIME cells
For production of replication-defective amphotropic murine
leukemia virions, Phoenix-ampho packaging cells were seeded ina 6-cm dish and transfected with 5 mg of retroviral vector using
TransIT 293 protocol (Mirus). 48 h after transfection, the medium
containing virions was cleared of cell debris by spinning at
2000 rpm for 10 min, aliquotted directly, and stored at 80 1C.
Retroviral infections were done by incubating 1 mL of virus
preparation with 1105 TIME cells and 8 mg/mL polybrene in a
6-well plate, ﬁrst, by centrifugation at 2000 rpm for 2 h at 37 1C,
and then for an additional 3 h in an incubator. 48 h after infection,
stable pooled cells were selected with the appropriate antibiotic,
2.5 mg/mL puromycin, 500 mg/mL G418, or 100 mg/mL hygromy-
cin (Cellgro, Mediatech, Inc.).Lentivirus production and infection of TIME cells
For production of vesicular stomatitis virus-G envelope-pseu-
dotyped lentiviral virions, HEK293T were seeded in a 10-cm dish
(5.5106 cells) and were cotransfected the next day with 8 mg
psPAX2, 4 mg pMD2.G, and 8 mg of lentiviral (pSIN-MCS or
pCGSW) construct using the TransIt 293 protocol (Mirus). 24 h
after transfection, the medium was changed, and at 48 and 72 h
post transfection, the medium containing the lentiviral virions
was harvested, ﬁltered through a 0.45-mM ﬁlter, aliquotted
directly, and stored at 80 1C. Lentiviral infections were done
by incubating 2 mL of virus preparation with 2105 TIME cells
overnight with 8 mg/mL polybrene. Cells were harvested 72 h post
infection and GFP expression in the pCGSW-transduced cells was
monitored by ﬂuorescent microscopy (Supplemental Fig. 1).RT-PCR to verify expression of KSHV genes from lentiviral constructs
Total RNA was isolated from TIME cells using the RNeasy Plus
kit (Qiagen). Approximately 2 mg of total RNA was used to make
cDNA with the SuperScript VILO cDNA Synthesis kit (Invitrogen).
Reactions without the addition of reverse transcriptase were used
as negative controls. Subsequently, 1 mL of cDNA was used in
a PCR reaction with primers to speciﬁc KSHV genes or cellular
GAPDH (Vart et al., 2007).Conditioned medium
Conditioned medium from lentivirus-infected or KSHV-
infected TIME cells was harvested 72 h or 24 h post infection
respectively. Cell debris was removed by centrifugation in a
tabletop centrifuge at 2000 rpm for 10 min, then free virions
were removed via centrifugation at 15,000 rpm for 2 h and the
clariﬁed medium was stored at 80 1C. Uninfected TIME cells
were serum starved for 2 h before treatment with conditioned
medium for 30 min.Acknowledgments
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